• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Norland gets clearance for Apollo

Article

Ultrasound-based bone densitometers may be attracting the most attention in the market, but investment continues in traditional dual-energy x-ray absorptiometry (DEXA) systems. One company that follows this philosophy is White Plains, NY-based Norland

Ultrasound-based bone densitometers may be attracting the most attention in the market, but investment continues in traditional dual-energy x-ray absorptiometry (DEXA) systems. One company that follows this philosophy is White Plains, NY-based Norland Medical Systems, which has received Food and Drug Administration 510(k) clearance for its low-cost Apollo DXA.

Apollo DXA is a heel-scanning system that will sell for less than $20,000. It features a scan time of under 15 seconds and can be operated from a hand-held control console. A laptop computer and a black-and-white inkjet printer are available as options with Apollo DXA.

Norland officially introduced Apollo DXA at the American College of Obstetricians and Gynecologists meeting last month in New Orleans, where the company also demonstrated its Paris ultrasound-based densitometer. Sales of Paris are already under way outside the U.S., and the company expects to receive FDA approval of its premarket approval application by the fall.

In other company news, Norland's financial results continue to reflect the uncertainty in the U.S. bone densitometry market (SCAN 4/1/98). In its first quarter (end-March), Norland's revenues dipped 52.4% to $2.1 million, compared with $4.3 million reported in the same period last year. The company posted a net loss of $1.9 million, compared with net income of $104,000 in 1997.

Norland is seeing an improvement in second-quarter product sales, however, and also believes that a recently announced deal with Tokai Financial Services will help spur stronger financial results. Tokai, based in Berwyn, PA, will provide product financing for U.S. purchasers of Norland's x-ray bone densitometers.

Related Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.